Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

RAREUltragenyx Pharmaceutical Inc.

Nasdaq · CIK 0001515673
Filer categoryLarge accelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts370

Identity from submissions API

NameUltragenyx Pharmaceutical Inc.
CIK0001515673
TickersRARE
ExchangesNasdaq
Entity typeoperating
CategoryLarge accelerated filer
SIC2834 Pharmaceutical Preparations
EIN272546083
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone415-483-8800
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)1

Former names

  • None listed.
Business address
60 LEVERONI COURT
NOVATO
CA
94949
CA
Mailing address
60 LEVERONI COURT
NOVATO
CA
94949
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

1150 filing rows loaded from submissions recent; extra archives: CIK0001515673-submissions-001.json (147 filings, 2011-03-16 to 2015-07-18).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001167557-26-000260 005-87964 261549265 34 8806
2026-11-10 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000734 005-87964 261538376 34 9326
2026-11-04 10-Q 10-Q 0001193125-26-445718 001-36276 261519398 34 11367635 1 1
2026-11-03 8-K 8-K 2.01,2.02,2.05,9.01 0001193125-26-445342 001-36276 261517414 34 547724 1 1
2026-10-30 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002100121-26-001144 005-87964 261507216 34 7321
2026-10-20 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001013594-26-001062 005-87964 261473765 34 19853
2026-10-19 4 4 0001193125-26-425032 4918
2026-10-19 8-K 8-K 8.01 0001193125-26-424739 001-36276 261467651 34 147881 1 1
2026-10-14 8-K 8-K 1.01 0001193125-26-421079 001-36276 261458414 34 149194 1 1
2026-10-07 8-K 8-K 1.01 0001193125-26-416251 001-36276 261445596 34 149887 1 1
2026-09-17 8-K 8-K 8.01 0001515673-26-000006 001-36276 261386705 34 146180 1 1
2026-09-15 4 4 0001193125-26-392233 4782
2026-09-15 144 xsl144X01/primary_doc.xml 0001950047-26-009497 001-36276 261381212 33 6592
2026-09-08 4 4 0001193125-26-384878 5143
2026-09-02 8-K 8-K 8.01 0001193125-26-380165 001-36276 261354688 34 145507 1 1
2026-08-19 8-K 8-K 8.01 0001193125-26-357185 001-36276 261296471 34 150074 1 1
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001493215-26-000161 005-87964 261276312 34 12508
2026-08-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001167557-26-000169 005-87964 261270355 34 8630
2026-08-11 8-K 8-K 8.01 0001193125-26-343525 001-36276 261260743 34 148045 1 1
2026-08-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000549 005-87964 261252387 34 8028
2026-08-05 10-Q 10-Q 0001193125-26-333233 001-36276 261240544 34 10751719 1 1
2026-08-04 8-K 8-K 2.02,9.01 0001193125-26-332802 001-36276 261238696 34 531302 1 1
2026-08-04 4 4 0001193125-26-332547 4718
2026-08-04 4 4 0001193125-26-332536 4754
2026-08-03 144 xsl144X01/primary_doc.xml 0001950047-26-007510 001-36276 261233161 33 6280
2026-07-31 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002100121-26-001001 005-87964 261226752 34 7322
2026-07-31 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-001487 005-87964 261226246 34 7339
2026-07-30 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-003116 005-87964 261221123 34 11077
2026-07-06 4 4 0001193125-26-296128 4755
2026-07-01 144 xsl144X01/primary_doc.xml 0001950047-26-006703 001-36276 261145410 33 8433
2026-06-15 4 4 0001796536-26-000007 4730
2026-06-15 4 4 0001677455-26-000002 4915
2026-06-15 144 xsl144X01/primary_doc.xml 0001950047-26-006115 001-36276 261091573 33 4844
2026-06-15 144 xsl144X01/primary_doc.xml 0001950047-26-006073 001-36276 261090932 33 5241
2026-06-12 S-8 S-8 0001193125-26-269040 333-296732 261085916 33 485864 1 1
2026-06-01 4 4 0001786335-26-000002 4755
2026-06-01 144 xsl144X01/primary_doc.xml 0001950047-26-005347 001-36276 261050787 33 8329
2026-05-18 4 4 0001397266-26-000002 6975
2026-05-18 4 4 0001713070-26-000002 8345
2026-05-18 4 4 0001924797-26-000002 6917
2026-05-18 4 4 0001796536-26-000004 7009
2026-05-18 4 4 0001380022-26-000002 6977
2026-05-18 4 4 0001193125-26-229224 6960
2026-05-18 4 4 0001193125-26-229222 6977
2026-05-18 144 xsl144X01/primary_doc.xml 0001950047-26-004713 001-36276 26994354 33 4727
2026-05-18 8-K 8-K 5.02,5.07,9.01 0001193125-26-228639 001-36276 26992007 34 348997 1 1
2026-05-12 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000302 005-87964 26967082 34 8027
2026-05-06 4 4 0001193125-26-208632 5121
2026-05-06 10-Q 10-Q 0001193125-26-206960 001-36276 26945079 34 9773200 1 1
2026-05-05 8-K 8-K 2.02,9.01 0001193125-26-206368 001-36276 26943007 34 456664 1 1
2026-05-04 4 4 0001193125-26-204402 4754
2026-05-01 144 xsl144X01/primary_doc.xml 0001950047-26-003887 001-36276 26932481 33 9896
2026-04-30 DEFA14A DEFA14A 0001515673-26-000004 001-36276 26924962 34 1561878
2026-04-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100121-26-000786 005-87964 26915328 34 7257
2026-04-24 4 4 0001193125-26-177470 7529
2026-04-20 4 4 0001193125-26-164308 9954
2026-04-20 4 4 0001193125-26-164297 7569
2026-04-20 4 4 0001193125-26-164289 7571
2026-04-20 4 4 0001193125-26-164281 7468
2026-04-20 4 4 0001193125-26-164267 7485
2026-04-20 4 4 0001193125-26-164257 7513
2026-04-20 4 4 0001193125-26-164247 7505
2026-04-02 4 4 0001193125-26-140702 4753
2026-04-02 8-K 8-K 8.01 0001193125-26-139084 001-36276 26830778 34 154700 1 1
2026-04-01 144 xsl144X01/primary_doc.xml 0001950047-26-003127 001-36276 26828285 33 9895
2026-03-30 8-K 8-K 8.01 0001193125-26-130498 001-36276 26810124 34 155109 1 1
2026-03-27 ARS ANNUAL REPORT TO SECURITY HOLDERS 0001308179-26-000177 001-36276 26807903 34 2336715
2026-03-27 DEFA14A DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS 0001308179-26-000175 001-36276 26807895 34 4453970
2026-03-27 DEF 14A DEFINITIVE PROXY STATEMENT 0001308179-26-000174 001-36276 26807861 34 17118437 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002574 005-87964 26805151 34 7080
2026-03-12 8-K 8-K 8.01 0001193125-26-103167 001-36276 26745798 34 162122 1 1
2026-03-10 4 4 0001193125-26-100309 5948
2026-03-10 144 xsl144X01/primary_doc.xml 0001950047-26-002450 001-36276 26739977 33 5977
2026-03-06 144 xsl144X01/primary_doc.xml 0001950047-26-002334 001-36276 26732393 33 5877
2026-03-03 4 4 0001193125-26-089287 7143
2026-03-03 4 4 0001193125-26-089282 7088
2026-03-03 4 4 0001193125-26-089278 7822
2026-03-03 4 4 0001193125-26-089111 7039
2026-03-03 4 4 0001193125-26-089109 6876
2026-03-03 4 4 0001193125-26-089107 9608
2026-03-03 4 4 0001193125-26-089104 7084
2026-03-03 4 4 0001193125-26-089102 6494
2026-03-03 144 xsl144X01/primary_doc.xml 0001950047-26-002108 001-36276 26715454 33 8720
2026-03-02 144 xsl144X01/primary_doc.xml 0001950047-26-002038 001-36276 26709203 33 7351
2026-02-23 8-K 8-K 8.01 0001193125-26-062568 001-36276 26662215 34 153313 1 1
2026-02-18 10-K 10-K 0001193125-26-057329 001-36276 26649716 34 19905587 1 1
2026-02-12 8-K 8-K 2.02,2.05,9.01 0001193125-26-048738 001-36276 26626311 34 566511 1 1
2026-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-26-000545 005-87964 26602082 34 11411
2026-02-03 4 4 0001193125-26-034832 4616
2026-02-03 8-K 8-K 8.01 0001193125-26-034474 001-36276 26590217 34 174107 1 1
2026-02-02 144 xsl144X01/primary_doc.xml 0001950047-26-000800 001-36276 26587911 33 6667
2026-01-30 8-K 8-K 8.01 0001193125-26-030590 001-36276 26580670 34 155289 1 1
2026-01-12 8-K 8-K 2.02,9.01 0001193125-26-009791 001-36276 26524690 34 227360 1 1
2026-01-05 4 4 0001193125-26-002410 4616
2026-01-02 144 xsl144X01/primary_doc.xml 0001950047-26-000020 001-36276 26502460 33 6668
2025-12-30 8-K 8-K 8.01 0001193125-25-337099 001-36276 251614388 34 153340 1 1
2025-12-30 4 4 0001193125-25-336619 4994
2025-12-29 8-K 8-K 8.01 0001193125-25-332422 001-36276 251603439 34 157987 1 1
2025-12-11 4 4 0001193125-25-315460 4617
2025-12-10 144 xsl144X01/primary_doc.xml 0001950047-25-010053 001-36276 251562018 33 5985
2025-11-05 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002839 005-87964 251452782 34 11257
2025-11-05 10-Q 10-Q 0001193125-25-265126 001-36276 251451036 34 11457593 1 1
2025-11-04 8-K 8-K 1.01,2.02,9.01 0001193125-25-264707 001-36276 251449182 34 570374 1 1
2025-10-30 8-K 8-K 8.01 0001193125-25-257538 001-36276 251432379 34 170873 1 1
2025-10-14 4 4 0001193125-25-238708 4781
2025-09-19 4 4 0001193125-25-209387 4803
2025-09-12 144 xsl144X01/primary_doc.xml 0001950047-25-007039 001-36276 251311709 33 4600
2025-09-12 4 4 0001677455-25-000005 4771
2025-09-08 8-K 8-K 8.01 0000950170-25-113553 001-36276 251300180 34 165507 1 1
2025-09-08 4 4 0000950170-25-113446 4996
2025-08-18 8-K 8-K 8.01 0000950170-25-109570 001-36276 251226342 34 154042 1 1
2025-08-06 10-Q 10-Q 0000950170-25-103290 001-36276 251186557 34 11235627 1 1
2025-08-05 8-K 8-K 2.02,9.01 0000950170-25-103026 001-36276 251184960 34 537180 1 1
2025-07-31 8-K 8-K 8.01 0000950170-25-100918 001-36276 251171856 34 154524 1 1
2025-07-18 S-8 S-8 0000950170-25-096912 333-288764 251134457 33 566182 1 1
2025-07-11 8-K 8-K 8.01 0000950170-25-095334 001-36276 251119450 34 155671 1 1
2025-07-09 8-K 8-K 8.01 0000950170-25-094806 001-36276 251113928 34 156162 1 1
2025-06-27 8-K 8-K 8.01 0000950170-25-090616 001-36276 251082301 34 152788 1 1
2025-06-23 4 4 0000950170-25-088878 4329
2025-06-20 144 xsl144X01/primary_doc.xml 0001950047-25-004490 001-36276 251061244 33 4750
2025-05-19 4 4 0000950170-25-074669 6806
2025-05-19 4 4 0000950170-25-074667 6823
2025-05-19 4 4 0000950170-25-074666 6872
2025-05-19 4 4 0000950170-25-074665 6850
2025-05-19 4 4 0000950170-25-074664 6838
2025-05-19 4 4 0000950170-25-074662 6840
2025-05-19 4 4 0000950170-25-074661 6780
2025-05-19 8-K 8-K 5.02,5.07,9.01 0000950170-25-074529 001-36276 25964934 34 341227 1 1
2025-05-07 10-Q 10-Q 0000950170-25-064726 001-36276 25918720 34 10005071 1 1
2025-05-06 8-K 8-K 2.02,9.01 0000950170-25-064473 001-36276 25917360 34 468317 1 1
2025-05-05 4 4 0000950170-25-063792 6391
2025-04-24 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001563 005-87964 25863911 34 11020
2025-03-28 ARS ANNUAL REPORT TO SECURITY HOLDERS 0001308179-25-000298 001-36276 25787445 34 9739612
2025-03-28 DEFA14A DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS 0001308179-25-000297 001-36276 25787418 34 4380974
2025-03-28 DEF 14A DEFINITIVE PROXY STATEMENT 0001308179-25-000296 001-36276 25787411 34 15243268 1 1
2025-03-10 4 4 0000950170-25-036056 5295
2025-03-04 4 4 0000950170-25-032802 8476
2025-03-04 4 4 0000950170-25-032798 6850
2025-03-04 4 4 0000950170-25-032794 11228
2025-03-04 4 4 0000950170-25-032785 12783
2025-03-04 4 4 0000950170-25-032779 13045
2025-03-04 4 4 0000950170-25-032773 11152
2025-03-04 4 4 0000950170-25-032767 10555
2025-03-04 4 4 0000950170-25-032764 10995
2025-03-04 4 4 0000950170-25-032750 7388
2025-03-03 4 4 0000950170-25-030639 10269
2025-02-28 144 xsl144X01/primary_doc.xml 0002007317-25-000222 001-36276 25690266 33 7143
2025-02-27 144 xsl144X01/primary_doc.xml 0001972362-25-000193 001-36276 25680551 33 7249
2025-02-19 10-K 10-K 0000950170-25-023312 001-36276 25641376 34 20817803 1 1
2025-02-13 8-K 8-K 2.02,9.01 0000950170-25-019854 001-36276 25620091 34 630918 1 1
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001020066-25-000013 005-87964 25613367 34 13561
2025-02-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-25-000076 005-87964 25604166 34 15260
2025-01-13 8-K 8-K 2.02,9.01 0000950170-25-004587 001-36276 25524970 34 234203 1 1
2024-12-31 4 4 0000950170-24-141485 5834
2024-12-30 144 xsl144X01/primary_doc.xml 0001971857-24-000911 001-36276 241590233 33 4922
2024-12-19 8-K 8-K 8.01 0000950170-24-138467 001-36276 241563491 34 156557 1 1
2024-12-19 8-K 8-K 8.01 0000950170-24-138250 001-36276 241561054 34 156872 1 1
2024-12-11 4 4 0000950170-24-135525 4839
2024-12-11 4 4 0000950170-24-135521 7096
2024-12-10 144 xsl144X01/primary_doc.xml 0001971857-24-000811 001-36276 241538598 33 4284
2024-11-14 SC 13G/A ULTRAGENYX PHARMACEUTICAL INC. 0000902664-24-006498 005-87964 241456997 34 63459
2024-11-12 8-K 8-K 8.01 0000950170-24-124458 001-36276 241442751 34 157682 1 1
2024-11-06 10-Q 10-Q 0000950170-24-121679 001-36276 241428784 34 10047829 1 1
2024-11-05 8-K 8-K 2.02,9.01 0000950170-24-121459 001-36276 241427473 34 468665 1 1
2024-10-11 4 4 0000950170-24-114378 4801
2024-10-07 8-K 8-K 8.01 0000950170-24-113085 001-36276 241356217 34 154245 1 1
2024-10-03 8-K 8-K 8.01 0000950170-24-112402 001-36276 241352008 34 156696 1 1
2024-09-18 4 4 0000950170-24-107677 5005
2024-09-05 4 4 0000950170-24-103811 5920
2024-09-05 4 4 0000950170-24-103807 5015
2024-09-03 144 xsl144X01/primary_doc.xml 0002002698-24-000359 001-36276 241274656 33 4887
2024-08-07 4 4 0000950170-24-092608 6109
2024-08-06 144 xsl144X01/primary_doc.xml 0002007317-24-000519 001-36276 241179796 33 4287
2024-08-02 10-Q 10-Q 0000950170-24-089488 001-36276 241168206 34 9776674 1 1
2024-08-01 8-K 8-K 2.02,9.01 0000950170-24-089263 001-36276 241166640 34 469997 1 1
2024-07-17 8-K 8-K 8.01 0000950170-24-084254 001-36276 241122259 34 161690 1 1
2024-07-12 S-8 S-8 0000950170-24-083195 333-280776 241114486 33 389332
2024-07-03 4 4 0000950170-24-081302 4335
2024-07-02 144 xsl144X01/primary_doc.xml 0001950047-24-005193 001-36276 241095130 33 5446
2024-06-21 8-K 8-K 5.02,5.07,9.01 0000950170-24-076222 001-36276 241060163 34 325860 1 1
2024-06-20 4 4 0000950170-24-075491 6847
2024-06-20 4 4 0000950170-24-075489 6845
2024-06-20 4 4 0000950170-24-075488 6830
2024-06-20 4 4 0000950170-24-075487 6857
2024-06-20 4 4 0000950170-24-075486 6787
2024-06-20 4 4 0000950170-24-075485 6879
2024-06-20 4 4 0000950170-24-075483 6813
2024-06-17 8-K 8-K 1.01,9.01 0001193125-24-162003 001-36276 241046909 34 638491 1 1
2024-06-14 424B5 424B5 0001193125-24-161716 333-277226 241045921 33 601902
2024-06-12 4 4 0000950170-24-072621 4782
2024-06-12 424B5 424B5 0001193125-24-160052 333-277226 241039350 33 577117
2024-06-12 144 xsl144X01/primary_doc.xml 0001950047-24-004699 001-36276 241039229 33 5290
2024-06-12 8-K 8-K 8.01 0000950170-24-072414 001-36276 241038384 34 153587 1 1
2024-06-12 8-K 8-K 8.01 0000950170-24-072119 001-36276 241037098 34 160844 1 1
2024-06-10 4 4 0000950170-24-071548 4598
2024-06-10 144 xsl144X01/primary_doc.xml 0001950047-24-004584 001-36276 241033818 33 4757
2024-06-10 UPLOAD filename1.pdf 0000000000-24-006612 001-36276 39582
2024-05-30 8-K 8-K 8.01,9.01 0000950170-24-066553 001-36276 241005133 34 162871 1 1
2024-05-17 CORRESP filename1.htm 0001193125-24-141579 44304
2024-05-03 4 4 0000950170-24-052788 4794
2024-05-03 10-Q 10-Q 0000950170-24-052346 001-36276 24910122 34 8314984 1 1
2024-05-02 8-K 8-K 2.02,9.01 0000950170-24-052052 001-36276 24908012 34 370210 1 1
2024-04-26 ARS ULTRAGENYX PHARMACEUTICAL INC. - ARS 0001308179-24-000611 001-36276 24884454 34 2147498
2024-04-26 DEFA14A ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A 0001308179-24-000610 001-36276 24884423 34 791135
2024-04-26 DEF 14A ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A 0001308179-24-000609 001-36276 24884408 34 5157641 1 1
2024-04-22 UPLOAD filename1.pdf 0000000000-24-004406 001-36276 43464
2024-04-19 4 4 0000950170-24-046055 4793
2024-04-18 4 4 0000950170-24-045670 4858
2024-04-15 8-K 8-K 8.01,9.01 0000950123-24-003302 001-36276 24843155 34 175096 1 1
2024-03-12 4 4 0000950170-24-029780 5135
2024-03-11 144 xsl144X01/primary_doc.xml 0001972362-24-000386 001-36276 24739627 33 10158
2024-03-11 4 4 0000950170-24-029040 8101
2024-03-07 144 xsl144X01/primary_doc.xml 0001950047-24-001996 001-36276 24730165 33 5908
2024-03-05 4 4 0000950170-24-026672 7724
2024-03-05 4 4 0000950170-24-026666 10669
2024-03-05 4 4 0000950170-24-026661 12098
2024-03-05 4 4 0000950170-24-026652 10614
2024-03-05 4 4 0000950170-24-026648 12145
2024-03-05 4 4 0000950170-24-026641 13183
2024-03-05 4 4 0000950170-24-026635 11792
2024-03-05 4 4 0000950170-24-026629 10636
2024-03-05 4 4 0000950170-24-026625 11386
2024-02-21 S-3ASR S-3ASR 0001193125-24-041577 333-277226 24660772 33 1207105
2024-02-21 10-K 10-K 0000950170-24-017879 001-36276 24659279 34 17403760 1 1
2024-02-15 8-K 8-K 2.02,9.01 0000950170-24-015856 001-36276 24643754 34 495500 1 1
2024-02-14 SC 13G/A rare13gadec23.txt 0000080255-24-000711 005-87964 34 6646
2024-02-14 SC 13G/A ULTRAGENYX PHARMACEUTICAL INC. 0000902664-24-001572 005-87964 24632370 34 62905
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-022166 005-87964 24629838 34 13018
2024-02-13 SC 13G rare_13g.htm 0000908834-24-000059 005-87964 24625345 34 55616
2024-02-08 4 FORM 4 SUBMISSION 0001209191-24-002989 6283
2024-02-08 SC 13G/A SEC SCHEDULE 13G 0000902219-24-000136 005-87964 24607353 34 37498
2024-02-07 144 xsl144X01/primary_doc.xml 0002007317-24-000082 001-36276 24604980 33 8124
2024-01-29 SC 13G/A us90400d1081_012924.txt 0001086364-24-005180 005-87964 24573156 34 13695
2024-01-08 8-K 8-K 2.02,9.01 0000950170-24-002655 001-36276 24518174 34 732186 1 1
2024-01-02 4 FORM 4 SUBMISSION 0001209191-24-000071 6517
2024-01-02 4 FORM 4 SUBMISSION 0001209191-24-000070 9330
2023-12-29 144 xsl144X01/primary_doc.xml 0002002698-23-000203 001-36276 231528338 33 10832
2023-12-21 8-K 8-K 5.03,9.01 0000950170-23-072192 001-36276 231505266 34 292788 1 1
2023-11-03 10-Q 10-Q 0000950170-23-058427 001-36276 231373923 34 11000594 1 1
2023-11-02 8-K 8-K 2.02,9.01 0000950170-23-058240 001-36276 231372566 34 567614 1 1
2023-10-24 4 FORM 4 SUBMISSION 0001209191-23-053487 9284
2023-10-23 4 FORM 4 SUBMISSION 0001209191-23-053351 10423
2023-10-23 144 xsl144X01/primary_doc.xml 0001950047-23-004591 001-36276 231340396 33 4664
2023-10-23 8-K 8-K 1.01,9.01 0001193125-23-260305 001-36276 231338472 34 548493 1 1
2023-10-20 424B5 424B5 0001193125-23-259557 333-253008 231335938 33 520939
2023-10-19 144 xsl144X01/primary_doc.xml 0001971857-23-000764 001-36276 231335182 33 4205
2023-10-19 FWP FWP 0001193125-23-258745 333-253008 231333148 34 35576
2023-10-17 424B5 424B5 0001193125-23-257669 333-253008 231329735 33 475885
2023-10-16 8-K 8-K 2.02,7.01,8.01,9.01 0001193125-23-256537 001-36276 231326251 34 2690608 1 1
2023-10-10 4 FORM 4 SUBMISSION 0001209191-23-052466 7470
2023-10-10 3 FORM 3 SUBMISSION 0001209191-23-052462 7415
2023-09-29 4 FORM 4 SUBMISSION 0001209191-23-050841 6751
2023-09-29 4 FORM 4 SUBMISSION 0001209191-23-050840 6733
2023-09-11 4 FORM 4 SUBMISSION 0001209191-23-048905 10460
2023-09-11 SC 13G/A SCHEDULE 13G/A 0001104659-23-099626 005-87964 231247415 34 12938
2023-09-08 8-K 8-K 5.02,9.01 0000950170-23-047138 001-36276 231243696 34 214068 1 1
2023-09-07 144 xsl144X01/primary_doc.xml 0001950047-23-003831 001-36276 231242961 33 6638
2023-09-06 4 FORM 4 SUBMISSION 0001209191-23-048491 5214
2023-09-06 4 FORM 4 SUBMISSION 0001209191-23-048489 7411
2023-09-05 144 xsl144X01/primary_doc.xml 0001972362-23-000777 001-36276 231237386 33 7793
2023-08-04 10-Q 10-Q 0000950170-23-038173 001-36276 231141515 34 11898403 1 1
2023-08-03 8-K 8-K 2.02,9.01 0000950170-23-037962 001-36276 231139980 34 625725 1 1
2023-07-12 8-K 8-K 5.02,7.01,9.01 0000950170-23-032604 001-36276 231083290 34 342996 1 1
2023-07-06 8-K 8-K 7.01,8.01,9.01 0000950170-23-031902 001-36276 231072149 34 230731 1 1
2023-06-30 144 xsl144X01/primary_doc.xml 0001950047-23-002004 001-36276 231062077 33 5272
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040269 4736
2023-06-21 4 FORM 4 SUBMISSION 0001209191-23-038885 5080
2023-06-13 8-K 8-K 5.02,5.07 0000950170-23-027644 001-36276 231010829 34 203324 1 1
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035692 7088
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035691 8964
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035690 8930
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035689 7120
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035688 7149
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035687 7153
2023-06-09 4 FORM 4 SUBMISSION 0001209191-23-035686 7137
2023-06-08 144 xsl144X01/primary_doc.xml 0001950047-23-001429 001-36276 231002629 33 4588
2023-06-08 S-8 S-8 0000950170-23-027029 333-272518 231002415 33 590080
2023-06-05 8-K 8-K 7.01,8.01,9.01 0000950170-23-026375 001-36276 23992745 34 264005 1 1
2023-05-19 4 FORM 4 SUBMISSION 0001209191-23-030931 5213
2023-05-18 144 xsl144X01/primary_doc.xml 0001950047-23-000769 001-36276 23936678 33 5898
2023-05-17 8-K 8-K 8.01 0000950170-23-022610 001-36276 23929687 34 160660 1 1
2023-05-10 4 FORM 4 SUBMISSION 0001209191-23-028585 7347
2023-05-05 4 FORM 4 SUBMISSION 0001209191-23-027601 5136
2023-05-05 10-Q 10-Q 0000950170-23-018017 001-36276 23890460 34 10093394 1 1
2023-05-04 144 xsl144X01/primary_doc.xml 0001950047-23-000410 001-36276 23890636 33 7584
2023-05-04 8-K 8-K 2.02,9.01 0000950170-23-017852 001-36276 23888738 34 458441 1 1
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026692 7681
2023-05-02 3 FORM 3 SUBMISSION 0001209191-23-026682 15847
2023-04-24 DEFA14A ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A 0001308179-23-000758 001-36276 23840506 34 818411
2023-04-24 DEF 14A ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A 0001308179-23-000757 001-36276 23840493 34 4954107 1 1
2023-04-18 4 FORM 4 SUBMISSION 0001209191-23-024685 6852
2023-03-23 8-K 8-K 5.02 0000950170-23-009543 001-36276 23756944 34 160832 1 1
2023-03-14 8-K 8-K 5.02 0000950170-23-007720 001-36276 23729282 34 163989 1 1
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016053 6728
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016047 11245
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016046 12932
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016045 11178
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016043 12954
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016042 12936
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016041 12532
2023-03-03 4 FORM 4 SUBMISSION 0001209191-23-016039 11213
2023-03-02 4 FORM 4 SUBMISSION 0001209191-23-014502 5031
2023-02-17 S-8 S-8 0000950170-23-003098 333-269840 23639708 33 286097
2023-02-17 10-K 10-K 0000950170-23-003096 001-36276 23639697 34 22020040 1 1
2023-02-16 8-K 8-K 2.02,9.01 0000950170-23-003048 001-36276 23638590 34 1156963 1 1
2023-02-14 SC 13G/A rare13gadec22.txt 0000080255-23-002627 005-87964 34 6810
2023-02-14 SC 13G ULTRAGENYX PHARMACEUTICAL INC. 0000902664-23-001730 005-87964 23623879 34 66878
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-017168 005-87964 23604556 34 12935
2023-02-06 SC 13G SEC SCHEDULE 13G 0000846087-23-000186 005-87964 23590231 34 37580
2023-02-03 SC 13G us90400d1081_020323.txt 0001306550-23-007094 005-87964 23584747 34 13450
2023-01-10 SC 13G/A form774.htm 0001623632-23-000009 005-87964 23519767 34 174215
2023-01-06 8-K 8-K 2.02,7.01,9.01 0000950170-23-000338 001-36276 23515319 34 758221 1 1
2023-01-03 4 FORM 4 SUBMISSION 0001209191-23-000276 6531
2022-12-22 4 FORM 4 SUBMISSION 0001209191-22-062400 5217
2022-12-09 SC 13G/A SEC SCHEDULE 13G 0001562230-22-000126 005-87964 221454459 34 18316
2022-11-10 8-K 8-K 5.02 0001193125-22-282661 001-36276 221377676 34 137986 1 1
2022-11-03 10-Q 10-Q 0000950170-22-021366 001-36276 221355511 34 12536709 1 1
2022-11-02 8-K 8-K 2.02,9.01 0000950170-22-021238 001-36276 221354181 34 1150714 1 1
2022-10-28 8-K 8-K 5.07 0000950170-22-020460 001-36276 221341953 34 163919 1 1
2022-10-17 4 FORM 4 SUBMISSION 0001209191-22-053884 5021
2022-10-14 4 FORM 4 SUBMISSION 0001209191-22-053647 4956
2022-09-19 4 FORM 4 SUBMISSION 0001209191-22-050670 5118
2022-09-15 8-K 8-K 5.02 0000950170-22-018538 001-36276 221245873 34 177160 1 1
2022-09-08 4 FORM 4 SUBMISSION 0001209191-22-049222 5305
2022-08-10 SC 13G/A rare13gajul22.txt 0000080255-22-002502 005-87964 34 6806
2022-07-29 10-Q 10-Q 0000950170-22-013411 001-36276 221116640 34 12724550 1 1
2022-07-28 8-K 8-K 2.02,9.01 0000950170-22-013372 001-36276 221115301 34 1111545 1 1
2022-07-18 8-K 8-K 1.01,2.01,7.01,8.01,9.01 0000950170-22-012761 001-36276 221089293 34 254540 1 1
2022-07-14 8-K 8-K 1.01,8.01,9.01 0000950170-22-012669 001-36276 221082251 34 747886 1 1
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039770 7155
2022-06-28 4 FORM 4 SUBMISSION 0001209191-22-039568 7107
2022-06-28 4 FORM 4 SUBMISSION 0001209191-22-039567 7114
2022-06-28 4 FORM 4 SUBMISSION 0001209191-22-039566 7122
2022-06-28 4 FORM 4 SUBMISSION 0001209191-22-039565 7134
2022-06-28 4 FORM 4 SUBMISSION 0001209191-22-039564 7057
2022-06-28 4 FORM 4 SUBMISSION 0001209191-22-039562 7090
2022-06-28 4 FORM 4 SUBMISSION 0001209191-22-039561 7124
2022-06-27 8-K 8-K 5.07 0000950170-22-012192 001-36276 221044684 34 186349 1 1
2022-06-22 4 FORM 4 SUBMISSION 0001209191-22-038774 5043
2022-05-17 8-K 8-K 8.01,9.01 0000950170-22-010158 001-36276 22932298 34 262108 1 1
2022-05-06 10-Q 10-Q 0000950170-22-007940 001-36276 22898139 34 9017985 1 1
2022-05-05 8-K 8-K 2.02,9.01 0000950170-22-007796 001-36276 22896039 34 949369 1 1
2022-04-28 DEFA14A ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A 0001308179-22-000295 001-36276 22866643 34 808243
2022-04-28 DEF 14A ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A 0001308179-22-000294 001-36276 22866616 34 2279945
2022-04-22 4 FORM 4 SUBMISSION 0001209191-22-025279 7377
2022-04-22 3 FORM 3 SUBMISSION 0001209191-22-025278 7285
2022-04-22 8-K 8-K 5.02 0000950170-22-005981 001-36276 22843426 34 166890 1 1
2022-04-19 4 FORM 4 SUBMISSION 0001209191-22-024699 4961
2022-03-15 4 FORM 4 SUBMISSION 0001209191-22-018829 5249
2022-03-09 SC 13G/A us90400d1081_030922.txt 0000834237-22-008958 005-87964 22726322 34 12569
2022-03-08 4 FORM 4 SUBMISSION 0001209191-22-016931 5197
2022-03-08 4 FORM 4 SUBMISSION 0001209191-22-016930 6976
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015833 11156
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015830 9264
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015823 9394
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015819 9541
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015815 9585
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015811 9656
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015806 9351
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015802 9357
2022-03-03 4 FORM 4 SUBMISSION 0001209191-22-015799 10127
2022-02-15 S-8 S-8 0001564590-22-005225 333-262751 22639543 33 202053
2022-02-15 10-K 10-K 0000950170-22-001284 001-36276 22639426 34 18379698 1 1
2022-02-14 SC 13G/A form69.htm 0001623632-22-000251 005-87964 22630100 34 278559
2022-02-14 SC 13G/A rare13gadec21.txt 0000080255-22-002104 005-87964 34 6785
2022-02-11 SC 13G/A SEC SCHEDULE 13G 0001562230-22-000068 005-87964 22617870 34 18225
2022-02-10 8-K 8-K 2.02,9.01 0000950170-22-001079 001-36276 22614017 34 1116186 1 1
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-018771 005-87964 22611077 34 12930
2022-02-03 SC 13G/A us90400d1081_020322.txt 0000834237-22-006251 005-87964 22589109 34 13438
2022-02-01 5 FORM 5 SUBMISSION 0001209191-22-005840 4866
2022-02-01 5 FORM 5 SUBMISSION 0001209191-22-005839 5724
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-005838 4956
2022-01-10 8-K 8-K 2.02,7.01,9.01 0000950170-22-000187 001-36276 22519817 34 275086 1 1
2022-01-07 8-K 8-K 8.01,9.01 0000950170-22-000122 001-36276 22516468 34 287577 1 1
2021-11-03 10-Q 10-Q 0000950170-21-002687 001-36276 211372886 34 11091509 1 1
2021-11-02 8-K 8-K 2.02,9.01 0000950170-21-002657 001-36276 211371471 34 1085423 1 1
2021-10-26 SC 13D/A SC 13D/A 0001193125-21-308036 43425
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060765 4956
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060760 4863
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060759 4979
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060756 6508
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060754 4949
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060752 4894
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060749 5724
2021-10-18 4 FORM 4 SUBMISSION 0001209191-21-060748 4993
2021-10-14 4 FORM 4 SUBMISSION 0001209191-21-060504 7253
2021-10-08 SC 13G/A SEC SCHEDULE 13G 0001422848-21-000160 005-87964 211314914 34 18170
2021-10-07 8-K 8-K 8.01,9.01 0000950170-21-002049 001-36276 211311099 34 1117085 1 1
2021-10-01 4 FORM 4 SUBMISSION 0001209191-21-058365 7234
2021-09-27 8-K 8-K 8.01,9.01 0000950170-21-001889 001-36276 211279028 34 1112978 1 1
2021-09-09 4 FORM 4 SUBMISSION 0001209191-21-055362 8861
2021-09-02 4 FORM 4 SUBMISSION 0001209191-21-054542 15182
2021-08-12 4 FORM 4 SUBMISSION 0001209191-21-051182 001-38942 211168662 34 7269
2021-08-12 SC 13D/A SC 13D/A 0001193125-21-244861 43345
2021-08-03 10-Q 10-Q 0001564590-21-039879 001-36276 211137295 34 11460794 1 1
2021-08-02 8-K 8-K 2.02,9.01 0000950170-21-000648 001-36276 211136143 34 1320036 1 1
2021-07-08 4 FORM 4 SUBMISSION 0001209191-21-045972 4863
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044165 7242
2021-06-30 3 FORM 3 SUBMISSION 0001209191-21-044164 7423
2021-06-30 8-K 8-K 5.02 0000950170-21-000408 001-36276 211060512 34 161805 1 1

Latest XBRL company facts

One latest value per concept from companyfacts (370 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 101.92M 2026-10-29 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
dei EntityPublicFloat Entity Public Float USD 3.40B 2025-06-30 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 45.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 166.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 242.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 136.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD -2.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD 1.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 4.55B 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD 6.74M 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 98.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD -1.26M 2016-01-01 2016-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 6.74M 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-11 0001564590-14-003472
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 98.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 80.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AllowanceForDoubtfulAccountsReceivableWriteOffs Accounts Receivable, Allowance for Credit Loss, Writeoff USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 17.4 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap Assets Assets USD 1.19B 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AssetsCurrent Assets, Current USD 544.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 342.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AssetsFairValueDisclosureRecurring Assets, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) USD 223.65M 2017-12-31 2017 FY 10-K 2018-02-21 0001564590-18-002535
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 2.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 319.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 918.63M 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002687
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 96,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002687
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 123,000 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002687
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 918.66M 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002687
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 317.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 116.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 135.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap AvailableForSaleSecuritiesGrossRealizedGainLossNet Available-for-sale Securities, Gross Realized Gain (Loss) USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-03 0000950170-21-002687
us-gaap BusinessAcquisitionsProFormaNetIncomeLoss Business Acquisition, Pro Forma Net Income (Loss) USD 341.70M 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-14 0001564590-20-004667
us-gaap BusinessAcquisitionsProFormaRevenue Business Acquisition, Pro Forma Revenue USD 18.50M 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-14 0001564590-20-004667
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 5.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap CapitalLeaseObligationsNoncurrent Capital Lease Obligations, Noncurrent USD 31.21M 2019-09-30 2019 Q3 10-Q 2019-11-06 0001564590-19-040541
us-gaap CapitalLeasesFutureMinimumPaymentsDueCurrent Capital Leases, Future Minimum Payments Due, Next Twelve Months USD 1.17M 2014-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 150.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -60.63M 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-21 0001564590-18-002535
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 113.33M 2018-06-30 2018 Q2 10-Q 2018-08-03 0001564590-18-018979
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 164.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -272.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 149,700 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 5.83M 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap CommonStockDividendsPerShareDeclared Common Stock, Dividends, Per Share, Declared USD/shares 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 250.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 72.17M 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058427
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 101.90M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap CommonStockValue Common Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -397.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ContractualObligation Contractual Obligation USD 8.31M 2019-12-31 2019 FY 10-K 2020-02-14 0001564590-20-004667
us-gaap ContractualObligationDueInFifthYear Contractual Obligation, to be Paid, Year Five USD 62,000 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ContractualObligationDueInFourthYear Contractual Obligation, to be Paid, Year Four USD 62,000 2016-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap ContractualObligationDueInNextTwelveMonths Contractual Obligation, to be Paid, Year One USD 30.41M 2020-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap ContractualObligationDueInSecondYear Contractual Obligation, to be Paid, Year Two USD 854,000 2020-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap ContractualObligationDueInThirdYear Contractual Obligation, to be Paid, Year Three USD 62,000 2017-12-31 2017 FY 10-K 2018-02-21 0001564590-18-002535
us-gaap ContractWithCustomerAssetNet Contract with Customer, Asset, after Allowance for Credit Loss USD 2.98M 2018-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 1.24M 2018-06-30 2018 Q2 10-Q 2018-08-03 0001564590-18-018979
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 4.44M 2022-06-30 2022 Q2 10-Q 2022-07-29 0000950170-22-013411
us-gaap ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination USD 2.53M 2017-01-01 2017-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 129.36M 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 19.60M 2014-02-05 2014 Q3 10-Q 2014-11-10 0001564590-14-005413
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 1.22M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-02 0001564590-19-028087
us-gaap CostOfGoodsSold Cost of Goods Sold (Deprecated 2018-01-31) USD 225,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 4.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DebtSecuritiesAvailableForSaleGainLoss Debt Securities, Available-for-sale, Gain (Loss) USD 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058427
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD -16.24M 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-14 0001564590-20-004667
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD 1.00M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -10.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 35.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 21.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 200,000 2015-07-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap DeferredRentCreditCurrent Deferred Rent Credit, Current USD 723,000 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 2.00M 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsEquityMethodInvestments Deferred Tax Assets, Equity Method Investments USD 8.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 1.36B 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 34.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 33.31M 2019-12-31 2019 FY 10-K 2020-02-14 0001564590-20-004667
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 6.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 511.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 4.00M 2012-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 0 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 426.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 34.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 1.35B 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 29.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DeferredTaxLiabilitiesNoncurrent Deferred Tax Liabilities, Net, Noncurrent USD 33.31M 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022136
us-gaap DefinedContributionPlanAdministrativeExpenses Defined Contribution Plan, Administrative Expense USD 123,000 2015-01-01 2015-03-31 2015 Q1 10-Q 2015-05-12 0001564590-15-003978
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 10.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 25.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) USD 119.40M 2014-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap DividendsPreferredStock Dividends, Preferred Stock USD 4.30M 2014-01-06 2014-02-05 2014 Q2 10-Q 2014-08-11 0001564590-14-003472
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -3.89 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -4.45 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-07-29 0000950170-22-013411
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -3.89 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.007 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.254 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0.051 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-14 0001564590-20-004667
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount USD 5.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent pure -0.009 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent pure 0.022 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.004 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.011 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.016 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure 0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount USD 14.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.025 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.008 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent pure -0.009 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.108 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.021 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD -1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap EffectOfExchangeRateOnCashContinuingOperations Effect of Exchange Rate on Cash, Continuing Operations USD 249,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity USD 6.74M 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 74.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Share-based Payment Arrangement, Amount Capitalized USD 2.78M 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-05 0001193125-25-265126
us-gaap EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) USD 9.00M 2016-01-01 2016-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 232.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap EquityMethodInvestments Equity Method Investments USD 26.33M 2019-09-30 2019 Q3 10-Q 2019-11-06 0001564590-19-040541
us-gaap EquitySecuritiesFvNiGainLoss Equity Securities, FV-NI, Gain (Loss) USD 512,000 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-05 0001193125-25-265126
us-gaap ExcessStockSharesAuthorized Excess Stock, Shares Authorized shares 275.00M 2014-09-30 2014 Q3 10-Q 2014-11-10 0001564590-14-005413
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings USD 3.32M 2014-01-01 2014-09-30 2015 Q3 10-Q 2015-11-10 0001564590-15-010240
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value USD 3.42M 2013-12-31 2015 Q3 10-Q 2015-11-10 0001564590-15-010240
us-gaap FinanceLeaseInterestExpense Finance Lease, Interest Expense USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-023312
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 183,000 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeaseLiabilityCurrent Finance Lease, Liability, Current USD 183,000 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 0 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeaseLiabilityPaymentsDue Finance Lease, Liability, Payment, Due USD 187,000 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Finance Lease, Liability, to be Paid, Year One USD 187,000 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeaseLiabilityPaymentsDueYearThree Finance Lease, Liability, to be Paid, Year Three USD 0 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeaseLiabilityPaymentsDueYearTwo Finance Lease, Liability, to be Paid, Year Two USD 0 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeaseLiabilityUndiscountedExcessAmount Finance Lease, Liability, Undiscounted Excess Amount USD 4,000 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap FinanceLeasePrincipalPayments Finance Lease, Principal Payments USD 149,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-10-27 0001564590-20-047991
us-gaap FinanceLeaseRightOfUseAssetAmortization Finance Lease, Right-of-Use Asset, Amortization USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-023312
us-gaap FinanceLeaseWeightedAverageDiscountRatePercent Finance Lease, Weighted Average Discount Rate, Percent pure 0.051 2022-12-31 2023 FY 10-K 2024-02-21 0000950170-24-017879
us-gaap FinancialLiabilitiesFairValueDisclosure Financial Liabilities Fair Value Disclosure USD 32.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-Lived Intangible Assets, Accumulated Amortization USD 21.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Finite-Lived Intangible Asset, Expected Amortization, after Year Five USD 11,000 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One USD 8,000 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Finite-Lived Intangible Asset, Expected Amortization, Year Five USD 7,000 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Finite-Lived Intangible Asset, Expected Amortization, Year Four USD 7,000 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three USD 7,000 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two USD 7,000 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap FiniteLivedIntangibleAssetsNet Finite-Lived Intangible Assets, Net USD 47,000 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 221,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap ForeignIncomeTaxExpenseBenefitContinuingOperations Foreign Income Tax Expense (Benefit), Continuing Operations USD 4.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap GainLossOnDispositionOfIntangibleAssets Gain (Loss) on Disposition of Intangible Assets USD 170.32M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 62.19M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-03 0001564590-17-021336
us-gaap Goodwill Goodwill USD 44.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap GoodwillAndIntangibleAssetImpairment Goodwill and Intangible Asset Impairment USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-15 0000950170-22-001284
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -565.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -402.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -6.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 4.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 100,000 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-023312
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD -7.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability USD 70.50M 2017-01-01 2017-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 145.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 1.30M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-023312
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -120.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD -1.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxReconciliationTaxContingenciesForeign Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount USD 5.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 12.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 266,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-06 0001564590-19-040541
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 20.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap IncreaseDecreaseInAccountsReceivableRelatedParties Increase (Decrease) in Accounts Receivable, Related Parties USD 125.55M 2020-01-01 2020-03-31 2021 Q1 10-Q 2021-05-05 0001564590-21-023501
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 3.78M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-06 0001564590-19-040541
us-gaap IncreaseDecreaseInDeferredIncomeTaxes Increase (Decrease) in Deferred Income Taxes USD -1.60M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-21 0000950170-24-017879
us-gaap IncreaseDecreaseInDeferredLiabilities Increase (Decrease) in Deferred Liabilities USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-023312
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD 8.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD -1.08M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-06 0001564590-19-040541
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -12.27M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-121679
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -16.58M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058427
us-gaap IncreaseDecreaseInPrepaidExpensesOther Increase (Decrease) in Prepaid Expenses, Other USD -2.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD -934,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-02-21 0001564590-18-002535
us-gaap IncreaseInRestrictedCash Increase in Restricted Cash USD 1.20M 2016-01-01 2016-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap IncrementalCommonSharesAttributableToCallOptionsAndWarrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants shares 140,752 2018-01-01 2018-03-31 2019 Q1 10-Q 2019-05-07 0001564590-19-016079
us-gaap IntangibleAssetsGrossExcludingGoodwill Intangible Assets, Gross (Excluding Goodwill) USD 197.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap IntangibleAssetsNetExcludingGoodwill Intangible Assets, Net (Excluding Goodwill) USD 170.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InterestAndDividendIncomeOperating Interest and Dividend Income, Operating USD 242,000 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-11 0001564590-14-003472
us-gaap InterestExpense Interest Expense USD 318,000 2010-04-22 2014-03-31 2014 Q1 10-Q 2014-05-12 0001564590-14-002047
us-gaap InventoryFinishedGoods Inventory, Finished Goods, Gross USD 29.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InventoryGross Inventory, Gross USD 61.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InventoryNet Inventory, Net USD 59.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InventoryNoncurrent Inventory, Noncurrent USD 2.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InventoryRawMaterials Inventory, Raw Materials, Gross USD 2.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InventoryWorkInProcess Inventory, Work in Process, Gross USD 30.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 14.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap InvestmentIncomeNetAmortizationOfDiscountAndPremium Investment Income, Net, Amortization of Discount and Premium USD -1.40M 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-11 0001564590-14-003472
us-gaap InvestmentsFairValueDisclosure Investments, Fair Value Disclosure USD 397.00M 2026-06-30 2026 Q2 10-Q 2026-08-05 0001193125-26-333233
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 6.40M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap LeaseCost Lease, Cost USD 17.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 43.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 1.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 15.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 2.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 7.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 8.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 10.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 2.52M 2019-09-30 2019 Q3 10-Q 2019-11-06 0001564590-19-040541
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 7.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap Liabilities Liabilities USD 1.56B 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 1.19B 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap LiabilitiesCurrent Liabilities, Current USD 389.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap LiabilitiesFairValueDisclosureRecurring Liabilities, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) USD 3.42M 2013-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap LongTermInvestments Long-term Investments USD 5.17M 2019-12-31 2020 Q3 10-Q 2020-10-27 0001564590-20-047991
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 13.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 286.42M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 53.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -71.03M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -337.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -89.48M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -395.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -245.87M 2016-01-01 2016-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD 7.00M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 11.72M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-03 0001564590-17-021336
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OperatingExpenses Operating Expenses USD 375.71M 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-03 0001564590-21-039879
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -354.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OperatingLeaseCost Operating Lease, Cost USD 12.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 36.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 12.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 24.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap OperatingLeasePayments Operating Lease, Payments USD 14.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 23.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 27.77M 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 5.96M 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 2.84M 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 2.83M 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 3.09M 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 4.59M 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 8.45M 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 6.40M 2018-01-01 2018-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.1 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 24.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherAssetsCurrent Other Assets, Current USD 41.37M 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-121679
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 63.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax USD -5.27M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -2.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -2.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 22.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 40.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 2.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 3.46M 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-11 0001564590-14-003472
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 318,000 2010-04-22 2014-03-31 2014 Q1 10-Q 2014-05-12 0001564590-14-002047
us-gaap PaymentsForProceedsFromOtherInvestingActivities Payments for (Proceeds from) Other Investing Activities USD 2.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PaymentsForRestructuring Payments for Restructuring USD 30.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PaymentsForTenantImprovements Payments for Tenant Improvements USD 3.47M 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap PaymentsForUnderwritingExpense Payments for Underwriting Expense USD 16.70M 2015-07-01 2015-07-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap PaymentsOfDividends Payments of Dividends USD 4.35M 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-11 0001564590-14-003472
us-gaap PaymentsOfDividendsPreferredStockAndPreferenceStock Payments of Ordinary Dividends, Preferred Stock and Preference Stock USD 4.35M 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap PaymentsToAcquireAvailableForSaleSecurities Payments to Acquire Available-for-sale Securities USD 648.52M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-10-27 0001564590-20-047991
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 227.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PaymentsToAcquireBusinessesNetOfCashAcquired Payments to Acquire Businesses, Net of Cash Acquired USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-19 0000950170-25-023312
us-gaap PaymentsToAcquireEquityMethodInvestments Payments to Acquire Equity Method Investments USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets USD 5.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 129.30M 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-11 0001564590-14-003472
us-gaap PaymentsToAcquireNotesReceivable Payments to Acquire Notes Receivable USD 1.88M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-10-27 0001564590-20-047991
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 4.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PreferredStockAccretionOfRedemptionDiscount Preferred Stock, Accretion of Redemption Discount USD 4.43M 2014-01-01 2014-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap PreferredStockAmountOfPreferredDividendsInArrears Preferred Stock, Amount of Preferred Dividends in Arrears USD 4.00M 2013-01-01 2013-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap PreferredStockDividendsAndOtherAdjustments Preferred Stock Dividends and Other Adjustments USD 4.81M 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 25.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2014-09-30 2014 Q3 10-Q 2014-11-10 0001564590-14-005413
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 53.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 89.01M 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 51.36M 2016-01-01 2016-12-31 2018 FY 10-K 2019-02-20 0001564590-19-003324
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 3.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 200.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ProceedsFromMinorityShareholders Proceeds from Noncontrolling Interests USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ProceedsFromPaymentsForOtherFinancingActivities Proceeds from (Payments for) Other Financing Activities USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ProceedsFromRepaymentsOfNotesPayable Proceeds from (Repayments of) Notes Payable USD 100,000 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap ProceedsFromRoyaltiesReceived Proceeds from Royalties Received USD 314.23M 2019-01-01 2019-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap ProceedsFromSaleOfAvailableForSaleSecurities Proceeds from Sale of Available-for-sale Securities USD 40.39M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-10-27 0001564590-20-047991
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 91.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ProceedsFromSaleOfIntangibleAssets Proceeds from Sale of Intangible Assets USD 170.32M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-12 0001564590-21-005610
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -258.57M 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-03 0001564590-21-039879
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 380.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 231.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap PurchaseObligation Purchase Obligation USD 479,000 2014-09-30 2014 Q3 10-Q 2014-11-10 0001564590-14-005413
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 4.94M 2017-01-01 2017-12-31 2019 FY 10-K 2020-02-14 0001564590-20-004667
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 508.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 75.03M 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 594,000 2014-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 652,000 2018-06-30 2018 Q2 10-Q 2018-08-03 0001564590-18-018979
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 1.82M 2018-06-30 2018 Q2 10-Q 2018-08-03 0001564590-18-018979
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 8.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 6.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap RestructuringCosts Restructuring Costs USD 30.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap RestructuringReserve Restructuring Reserve USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -4.93B 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 523.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 13.20M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-10-27 0001564590-20-047991
us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Sale of Stock, Number of Shares Issued in Transaction shares 706,072 2014-07-01 2014-07-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 120 2015-07-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap SalesRevenueGoodsNet Sales Revenue, Goods, Net (Deprecated 2018-01-31) USD 1.31M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap SalesRevenueNet Revenue, Net (Deprecated 2018-01-31) USD 10.68M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-08 0001564590-18-011341
us-gaap SellingGeneralAndAdministrativeExpense Selling, General and Administrative Expense USD 273.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 38.36M 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-03 0001564590-18-018979
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.65 2015-01-01 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.018 2015-01-01 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.016 2013-01-01 2013-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.007 2013-01-01 2013-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 6.50M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 66.31 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 4.90M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-21 0000950170-24-017879
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 1.70M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 1.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 22.92 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares shares 2.90M 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 0 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 8.90M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 60.87 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 0 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 0 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 8.70M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 61.24 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 46.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 38.57 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 73.53 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 41.75 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price USD/shares 13.3 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable shares 898,924 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding shares 3.83M 2015-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap ShortTermInvestments Short-term Investments USD 568.03M 2020-09-30 2020 Q3 10-Q 2020-10-27 0001564590-20-047991
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 63,000 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-07 0001564590-19-016079
us-gaap StateAndLocalIncomeTaxExpenseBenefitContinuingOperations State and Local Income Tax Expense (Benefit), Continuing Operations USD -3.00M 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -376.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 3.135 2014-01-16 2014-01-17 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 129.36M 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 121.71M 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD -2.07M 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-27 0001564590-15-002066
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests USD 7.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap TreasuryStockCommonShares Treasury Stock, Common, Shares shares 300,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap TreasuryStockDeferredEmployeeStockOwnershipPlan Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares USD 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap TreasuryStockShares Treasury Stock, Shares shares 7,812 2023-03-31 2023 Q1 10-Q 2023-05-05 0000950170-23-018017
us-gaap TreasuryStockValue Treasury Stock, Value USD 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap UndistributedEarningsOfForeignSubsidiaries Undistributed Earnings of Foreign Subsidiaries USD 17.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 111.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 1.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2022-12-31 2022 FY 10-K 2023-02-17 0000950170-23-003096
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 15.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 1.00M 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 148.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap VariableLeaseCost Variable Lease, Cost USD 5.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-18 0001193125-26-057329
us-gaap WarrantsNotSettleableInCashFairValueDisclosure Warrants Not Settleable in Cash, Fair Value Disclosure USD 6.70M 2014-01-30 2016 FY 10-K 2017-02-17 0001564590-17-001714
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 101.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 69.72M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-07-29 0000950170-22-013411
us-gaap WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation shares 201,033 2013-01-01 2013-12-31 2015 FY 10-K 2016-02-26 0001564590-16-013430
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 101.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-445718

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →